
Opinion|Videos|January 15, 2025
Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies
Panelists discuss how hepatotoxicity risks vary among second-line primary biliary cholangitis (PBC) treatments, with seladelpar and elafibranor showing favorable hepatic safety profiles compared to obeticholic acid, though all require regular liver function monitoring and dose adjustments based on individual patient response and disease severity.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Hepatotoxicity is a key safety concern in PBC treatment. How do therapies like seladelpar, elafibranor, and obeticholic acid compare in terms of hepatotoxicity risk, and what monitoring strategies are recommended?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
2
Elevating Precision Medicine in Breast Cancer Care
3
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
4
FDA Clears First Single-Inhaler Triple Therapy for Asthma
5














































































































